CN105985336A - 阿哌沙班n-1晶型的制备方法 - Google Patents
阿哌沙班n-1晶型的制备方法 Download PDFInfo
- Publication number
- CN105985336A CN105985336A CN201510077172.3A CN201510077172A CN105985336A CN 105985336 A CN105985336 A CN 105985336A CN 201510077172 A CN201510077172 A CN 201510077172A CN 105985336 A CN105985336 A CN 105985336A
- Authority
- CN
- China
- Prior art keywords
- eliquis
- preparation
- solvent
- crystal formation
- evaporated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 239000013078 crystal Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 229960003886 apixaban Drugs 0.000 title abstract description 4
- 239000002904 solvent Substances 0.000 claims abstract description 19
- 239000003495 polar organic solvent Substances 0.000 claims abstract description 10
- 238000010438 heat treatment Methods 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 45
- 229940047562 eliquis Drugs 0.000 claims description 40
- 230000015572 biosynthetic process Effects 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 abstract description 4
- 230000008025 crystallization Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000001704 evaporation Methods 0.000 abstract 1
- 230000008020 evaporation Effects 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000004821 distillation Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000000203 mixture Substances 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- -1 Eliquis Compound Chemical class 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229950010535 razaxaban Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510077172.3A CN105985336B (zh) | 2015-02-13 | 2015-02-13 | 阿哌沙班n-1晶型的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510077172.3A CN105985336B (zh) | 2015-02-13 | 2015-02-13 | 阿哌沙班n-1晶型的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105985336A true CN105985336A (zh) | 2016-10-05 |
CN105985336B CN105985336B (zh) | 2018-07-17 |
Family
ID=57041372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510077172.3A Active CN105985336B (zh) | 2015-02-13 | 2015-02-13 | 阿哌沙班n-1晶型的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105985336B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108864090A (zh) * | 2018-08-03 | 2018-11-23 | 扬子江药业集团上海海尼药业有限公司 | 一种阿哌沙班n-1晶体的制备方法 |
CN110862389A (zh) * | 2018-08-28 | 2020-03-06 | 江苏康缘药业股份有限公司 | 一种阿哌沙班晶型的制备方法 |
WO2021056850A1 (zh) * | 2019-09-26 | 2021-04-01 | 浙江天宇药业股份有限公司 | 阿哌沙班与羧酸形成的共晶及其制备方法 |
WO2022239735A1 (ja) * | 2021-05-10 | 2022-11-17 | ダイト株式会社 | アピキサバンの精製方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006078331A2 (en) * | 2005-01-19 | 2006-07-27 | Bristol-Myers Squibb Company | Crystallization via high-shear transformation |
CN103360391A (zh) * | 2013-08-06 | 2013-10-23 | 齐鲁制药有限公司 | 阿哌沙班新晶型及其制备方法 |
CN103539795A (zh) * | 2013-03-18 | 2014-01-29 | 齐鲁制药有限公司 | 阿哌沙班的多晶型及其制备方法 |
-
2015
- 2015-02-13 CN CN201510077172.3A patent/CN105985336B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006078331A2 (en) * | 2005-01-19 | 2006-07-27 | Bristol-Myers Squibb Company | Crystallization via high-shear transformation |
CN103539795A (zh) * | 2013-03-18 | 2014-01-29 | 齐鲁制药有限公司 | 阿哌沙班的多晶型及其制备方法 |
CN103360391A (zh) * | 2013-08-06 | 2013-10-23 | 齐鲁制药有限公司 | 阿哌沙班新晶型及其制备方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108864090A (zh) * | 2018-08-03 | 2018-11-23 | 扬子江药业集团上海海尼药业有限公司 | 一种阿哌沙班n-1晶体的制备方法 |
CN110862389A (zh) * | 2018-08-28 | 2020-03-06 | 江苏康缘药业股份有限公司 | 一种阿哌沙班晶型的制备方法 |
WO2021056850A1 (zh) * | 2019-09-26 | 2021-04-01 | 浙江天宇药业股份有限公司 | 阿哌沙班与羧酸形成的共晶及其制备方法 |
WO2022239735A1 (ja) * | 2021-05-10 | 2022-11-17 | ダイト株式会社 | アピキサバンの精製方法 |
JP7498147B2 (ja) | 2021-05-10 | 2024-06-11 | ダイト株式会社 | アピキサバンの精製方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105985336B (zh) | 2018-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105985336A (zh) | 阿哌沙班n-1晶型的制备方法 | |
CN103570621B (zh) | 一种(-)-石杉碱甲的制备 | |
CN103108874A (zh) | 用于制备双嘧达莫的方法 | |
CN108358810A (zh) | 基于天然薄荷醇为原料合成的凉味剂ws-3中手性右旋体的去除方法 | |
CN102399200B (zh) | 一种利用悬浮结晶法制备利奈唑胺晶型ⅰ的方法 | |
CN104911031A (zh) | 一种香茅油抑菌活性物质的提取方法 | |
JP2018502165A5 (zh) | ||
CN106892918B (zh) | 一种从吴茱萸中制备吴茱萸次碱的新方法 | |
CN105237437B (zh) | 一种恩他卡朋杂质化合物及其制备方法 | |
CN106632280A (zh) | 一种制备盐酸阿呋唑嗪的方法 | |
CN104556100B (zh) | 一种硼硅β分子筛中有机胺模板剂的脱除方法 | |
CN104098638A (zh) | 一种醋酸去氢表雄酮的制备方法 | |
CN106632145B (zh) | 沃替西汀氢溴酸盐晶型α的新制备方法 | |
CN101781243B (zh) | 医药中间体、其制备方法和用其制备伊潘立酮的方法 | |
CN109970535A (zh) | 一种β-紫罗兰酮的制备方法 | |
CN102464610B (zh) | 一种美替拉酮的制备方法 | |
CN107056706A (zh) | 一种用于制备盐酸伊伐布雷定α晶型的方法 | |
CN107556308A (zh) | 1‑芳基‑1H‑吡啶[3,4‑b]吲哚‑3‑羧酸甲酯衍生物的不对称合成 | |
CN107602412A (zh) | 一种醛油甲醇溶液的制备及提纯方法 | |
CN102461974A (zh) | 从酒糟制备食品抗氧剂的方法 | |
EP4188905B1 (en) | Method for the purification of vilanterol trifenatate | |
CN106432221B (zh) | 一种甲溴后马托品的精制方法 | |
CN111440221B (zh) | 一种以黄杞叶为原料制备得到的落新妇苷及其制备方法 | |
CN106496221A (zh) | 一种制备阿哌沙班n‑1 晶型的方法 | |
WO2013149571A1 (zh) | 人参皂苷c-k的两种晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 312500 No. 800, Xinchang Avenue, Yulin street, Xinchang County, Shaoxing City, Zhejiang Province Patentee after: ZHEJIANG JINGXIN PHARMACEUTICAL Co.,Ltd. Country or region after: China Patentee after: Shaoxing Jingxin Pharmaceutical Co.,Ltd. Patentee after: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. Address before: 312500 No. 800, Xinchang Avenue, Yulin street, Xinchang County, Shaoxing City, Zhejiang Province Patentee before: ZHEJIANG JINGXIN PHARMACEUTICAL Co.,Ltd. Country or region before: China Patentee before: SHANGYU JINGXIN PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |